Takeda Pharmaceuticals USA Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Takeda Pharmaceuticals USA Inc.
Supreme Court nominee issued three decisions on Hatch-Waxman regime as district court judge, including case in which she ruled against the FDA’s denial of orphan drug designation and another in which she deferred to the agency’s view on exclusivity. Her analysis of facts may play a role if the court takes up a case on administrative agency deference.
The biopharma market has been highly active throughout the COVID-19 pandemic with a substantial focus on strategic alliances between 2020-H1 2021. Partnership deals present exciting liquidity and risk mitigation opportunities for early-stage companies. Small molecules still comprise the largest segment of partnered drugs, but alliances for other modalities are on the rise.
Research on generic drug coverage in Medicare Part D plans finds access unobstructed for majority of lower cost alternatives. However, study may offer incomplete picture, generic and biosimilar advocates say.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.